In a report released today, Yihan Li from Barclays maintained a Hold rating on Roche Holding AG, with a price target of CHF275.00. The company’s shares closed yesterday at $362.85.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Li covers the Healthcare sector, focusing on stocks such as Galderma Group AG, Roche Holding AG, and Novo Nordisk. According to TipRanks, Li has an average return of 12.2% and an 80.00% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $349.42 average price target.
Based on Roche Holding AG’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $15.92 billion and a net profit of $3.71 billion. In comparison, last year the company earned a revenue of $30.76 billion and had a net profit of $6.26 billion
Read More on RHHVF:
Disclaimer & DisclosureReport an Issue
- Exicure appoints Josephine Cardarelli as president, CSO
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Weekly: White House announces drug pricing deal with Pfizer
- FDA approves Genentech’s Tecentriq + Lurbinectedin in ES-SCLC
- FDA approves combo of Jazz’s lurbinectedin and Roche’s atezolizumab for ES-SCLC
/Microsoft%20sign%20at%20the%20headquarters%20by%20VDB%20Photos%20via%20Shutterstock.jpg)
